<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325180</url>
  </required_header>
  <id_info>
    <org_study_id>QA620</org_study_id>
    <nct_id>NCT02325180</nct_id>
  </id_info>
  <brief_title>Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia</brief_title>
  <official_title>Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sumatera Utara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open label, randomised controlled trial to assess the safety and
      efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in children and adults
      with uncomplicated Plasmodium falciparum malaria infection. Molecular markers for
      antimalarial resistance will also be assessed and the presence of molecular markers in the
      parasites will be associated with treatment outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Artemisinin-based combination therapy (ACT) is the current recommended treatment by WHO for
      uncomplicated falciparum malaria. It is highly effective with few adverse effects. The
      artemisinin component is combined with a partner drug with a longer half-life to ensure the
      clearance of the remaining parasites after rapid reduction by artemisinin.

      ACT is used as first-line treatment for uncomplicated P. falciparum infection in Indonesia
      since 2004. There are 3 combinations available in the country including
      artesunate-amodiaquine (AS-AQ), dihydroartemisinin-piperaquine (DHA-PQ) and
      artemether-lumefantrine (AL). Studies at different sites across Indonesia have shown various
      efficacy. Yet, there is an increased concern of reduced susceptibility of P. falciparum to
      artemisinin in neighbouring countries. Therefore, there is a need to evaluate and monitor the
      efficacies of these combinations in Indonesia.

      Molecular markers are an important tool for detecting and monitoring the presence of
      antimalarial resistance. Their significant implication is to geographically map the extent of
      resistant-parasites, thus enabling strategies for their control and elimination to be applied
      before the inevitably increase in the disease burden occurs. Different markers have been used
      to identify antimalarial resistance and recently a molecular marker for artemisinin
      susceptibility in P. falciparum has also been proposed. The presence of these markers in
      parasites from our study will also be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine</measure>
    <time_frame>42 days</time_frame>
    <description>Early treatment failure, late treatment failure, adequate clinical and parasitological response Proportion of participants with Adequate Clinical and Parasitological Response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parasite clearance times</measure>
    <time_frame>3 days</time_frame>
    <description>Parasite reduction ratio, parasite clearance half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever clearance times</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of molecular markers and the impact on treatment outcomes</measure>
    <time_frame>42 days</time_frame>
    <description>Pfcrt, Pfmdr1, Pfk13 and any other important molecular markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of gametocyte</measure>
    <time_frame>42 days</time_frame>
    <description>Proportion of patients with gametocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of other Plasmodium species</measure>
    <time_frame>42 days</time_frame>
    <description>Plasmodium vivax, Plasmodium malariae, Plasmodium ovale spp, Plasmodium knowlesi</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematological recovery</measure>
    <time_frame>28 days</time_frame>
    <description>Haemoglobin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">338</enrollment>
  <condition>Malaria, Falciparum</condition>
  <arm_group>
    <arm_group_label>DHA-PQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet of dihydroartemisinin-piperaquine consists of 40 mg of dihydroartemisinin and 320 mg of piperaquine. DHA-PQ is administered once daily for 3 days (at enrolment, hour 24 and you 48). Dosing should be given based on body weight. Daily dose for dihydroartemisinin is 2.25 mg/kg (total 6.75 mg/kg) and for piperaquine is 18 mg/kg (total 54 mg/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half a tablet of artemether-lumefantrine consists of 20 mg of artemether and 120 mg of lumefantrine is given per 5 kg body weight. AL is administered as 6-dose regimens given twice daily for 3 days (at enrolment, hour 8, hour 24, hour 36, hour 48 and hour 60).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin-Piperaquine</intervention_name>
    <arm_group_label>DHA-PQ</arm_group_label>
    <other_name>Duo-Cotecxin</other_name>
    <other_name>Artekin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine</intervention_name>
    <arm_group_label>AL</arm_group_label>
    <other_name>Coartem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  All patients per 6 months of age

          -  Fever as defined by axillary temperature &gt; 37.5 C or history of fever during the 48
             hours before recruitment

          -  Infection with P. falciparum detected by microscopy

          -  Parasitaemia &gt; 250 /uL blood

          -  Ability to swallow oral medication

          -  Ability and willingness to comply with the protocol for the duration of the study and
             to comply with the study visit schedule

          -  Informed consent from the patient or from a parent or guardian in the case of children

          -  Absence of history to hypersensitive reactions or contraindication to antimalarial
             drugs

          -  Not currently consuming antibiotic with antimalarial activity (such as cotrimoxazole,
             macrolides, tetracycline or doxycycline)

        Exclusion Criteria:

          -  Presence of general danger signs in children under 5 years or signs of severe
             falciparum malaria according to the definitions of WHO (2000)

          -  Presence of severe malnutrition according to WHO child growth standards

          -  Presence of febrile conditions caused by diseases other than malaria

          -  Presence of severe anemia (Hemoglobin &lt; 7 gr/dL)

          -  Received any of the study drugs within the past 4 weeks

          -  Received any antimalarial within the last 2 weeks

          -  Recurrent vomiting )necessitating more than a single repeat dose)

          -  Pregnant (demonstrated by positive result of b-HCG in women of childbearing age

          -  Lactating mother
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin J Sutherland, BSc PhD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Primary health centres</name>
      <address>
        <city>Kuala Langkat</city>
        <state>North Sumatera</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary health centres</name>
      <address>
        <city>Tanjung Tiram</city>
        <state>North Sumatera</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulau-pulau Batu health centres</name>
      <address>
        <city>Tello island</city>
        <state>North Sumatera</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Guidelines for the Treatment of Malaria. 2nd edition. Geneva: World Health Organization; 2010.</citation>
    <PMID>25473692</PMID>
  </reference>
  <reference>
    <citation>White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet. 2014 Feb 22;383(9918):723-35. doi: 10.1016/S0140-6736(13)60024-0. Epub 2013 Aug 15. Review.</citation>
    <PMID>23953767</PMID>
  </reference>
  <reference>
    <citation>Fairhurst RM, Nayyar GM, Breman JG, Hallett R, Vennerstrom JL, Duong S, Ringwald P, Wellems TE, Plowe CV, Dondorp AM. Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg. 2012 Aug;87(2):231-41. Review.</citation>
    <PMID>22855752</PMID>
  </reference>
  <reference>
    <citation>Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM; Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008 Dec 11;359(24):2619-20. doi: 10.1056/NEJMc0805011. Epub 2008 Dec 8.</citation>
    <PMID>19064625</PMID>
  </reference>
  <reference>
    <citation>Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009 Jul 30;361(5):455-67. doi: 10.1056/NEJMoa0808859. Erratum in: N Engl J Med. 2009 Oct 22;361(17):1714.</citation>
    <PMID>19641202</PMID>
  </reference>
  <reference>
    <citation>White NJ. Malaria: a molecular marker of artemisinin resistance. Lancet. 2014 Apr 26;383(9927):1439-1440. doi: 10.1016/S0140-6736(14)60656-5.</citation>
    <PMID>24766952</PMID>
  </reference>
  <reference>
    <citation>Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Ménard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Ménard D. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014 Jan 2;505(7481):50-5. doi: 10.1038/nature12876. Epub 2013 Dec 18.</citation>
    <PMID>24352242</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2014</study_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACT</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <keyword>malaria</keyword>
  <keyword>efficacy</keyword>
  <keyword>Indonesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Artemisinine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

